Hikma Pharmaceuticals PLC
HKMPYOTCHealthcare● Active
$39.08
+$0.08(+0.21%)
Market Cap$4.3B
P/E Ratio—
52W High$56.91
52W Low$31.8
Hikma Pharmaceuticals PLC (HKMPY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HKMPY · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 24, 2026EPS Actual
$1.48
Revenue
$1.68B
Est. $1.68B · +0.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 24, 2026
After Market Close
HKMPY reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 24, 2026 | — | $1.48 | — | $1.68B | $1.68B | +0.0% |
| — Q3 FY2025 | Aug 7, 2025 | — | $2.14 | — | $1.66B | — | — |
| — Q1 FY2025 | Feb 26, 2025 | — | $0.59 | — | $1.54B | — | — |
| — Q3 FY2024 | Aug 8, 2024 | — | $1.01 | — | $1.57B | — | — |
| — Q2 FY2024 | Apr 25, 2024 | — | $0.52 | — | $1.44B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | $1.18 | — | $1.43B | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.14 | — | $1.37B | — | — |
| — Q2 FY2022 | Jun 30, 2022 | — | $1.52 | — | $1.21B | — | — |
Q1 FY2026
Feb 24, 2026
EPS Actual
$1.48
EPS Est.
—
EPS Surpr.
—
Revenue
$1.68B
Q3 FY2025
Aug 7, 2025
EPS Actual
$2.14
EPS Est.
—
EPS Surpr.
—
Revenue
$1.66B
Q1 FY2025
Feb 26, 2025
EPS Actual
$0.59
EPS Est.
—
EPS Surpr.
—
Revenue
$1.54B
Q3 FY2024
Aug 8, 2024
EPS Actual
$1.01
EPS Est.
—
EPS Surpr.
—
Revenue
$1.57B
Q2 FY2024
Apr 25, 2024
EPS Actual
$0.52
EPS Est.
—
EPS Surpr.
—
Revenue
$1.44B
Q2 FY2023
Jun 30, 2023
EPS Actual
$1.18
EPS Est.
—
EPS Surpr.
—
Revenue
$1.43B
Q4 FY2022
Dec 31, 2022
EPS Actual
$0.14
EPS Est.
—
EPS Surpr.
—
Revenue
$1.37B
Q2 FY2022
Jun 30, 2022
EPS Actual
$1.52
EPS Est.
—
EPS Surpr.
—
Revenue
$1.21B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $1.7B | $1.7B | $1.7B | 1 |
| Q3 FY2025 | $1.7B | $1.7B | $1.7B | 1 |
| Q2 FY2025 | $1.7B | $1.7B | $1.7B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 24, 2026 | — | $43.75 | $44.62 | +1.99% |
| — Q3 FY2025 | Aug 7, 2025 | — | $51.72 | $47.56 | -8.04% |
| — Q1 FY2025 | Feb 26, 2025 | — | $58.00 | $54.80 | -5.52% |
| — Q3 FY2024 | Aug 8, 2024 | — | $47.84 | $50.70 | +5.98% |
| — Q2 FY2024 | Apr 25, 2024 | — | $46.50 | $46.50 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $45.94 | $45.94 | +0.00% |
| — Q4 FY2022 | Dec 31, 2022 | — | $36.95 | $39.35 | +6.50% |
| — Q2 FY2022 | Jun 30, 2022 | — | $40.10 | $41.11 | +2.52% |
Q1 FY2026+1.99%
Report Date
Feb 24, 2026
EPS Beat/Miss
—
Price Before
$43.75
Price After
$44.62
Q3 FY2025-8.04%
Report Date
Aug 7, 2025
EPS Beat/Miss
—
Price Before
$51.72
Price After
$47.56
Q1 FY2025-5.52%
Report Date
Feb 26, 2025
EPS Beat/Miss
—
Price Before
$58.00
Price After
$54.80
Q3 FY2024+5.98%
Report Date
Aug 8, 2024
EPS Beat/Miss
—
Price Before
$47.84
Price After
$50.70
Q2 FY2024+0.00%
Report Date
Apr 25, 2024
EPS Beat/Miss
—
Price Before
$46.50
Price After
$46.50
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$45.94
Price After
$45.94
Q4 FY2022+6.50%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$36.95
Price After
$39.35
Q2 FY2022+2.52%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$40.10
Price After
$41.11
Beat Rate0 / 8 quarters
Largest Move-8.04% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HKMPY ends December
Hikma Pharmaceuticals PLC (HKMPY) most recently reported earnings on February 24, 2026 for Q1 FY2026, posting EPS of $1.48 (in line with the analyst consensus of —). The next HKMPY earnings date is expected around September 1, 2026.
Each quarter, investors track HKMPY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HKMPY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HKMPY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HKMPY earnings · 4 questionsHikma Pharmaceuticals PLC's next earnings report is expected around September 1, 2026. HKMPY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HKMPY historically reports after market close (AMC).
HKMPY earnings datewhen is HKMPY earningsHKMPY next earnings datewhen does HKMPY report earningsHKMPY earnings calendar
▸ Source: FMP · Hikma Pharmaceuticals PLC SEC filings · US GAAP · Hikma Pharmaceuticals PLC SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026